Microbiome – October 2020 Microbiome – October 2020 $275 million finding raised by microbiome players in September 2020 20 Oct 2020 Finch Therapeutics raised $90 million Series D financing to advance its pipeline of oral microbiome drugs, from multiple investors […]
Microbiome – October 2020 Microbiome – October 2020 Finch Therapeutics presented positive data from its pivotal Phase 2 trial of CP101 in recurrent C. difficile infections 13 Oct 2020 CP101 (GI microbiome modulator) – Finch Therapeutics Finch Therapeutics presented data […]
Microbiome – October 2020 Microbiome – October 2020 Vedanta Biosciences presented additional pharmacokinetics data from Phase 1 Study of VE202 for Inflammatory Bowel Disease 12 Oct 2020 VE202 (Regulatory T-lymphocyte modulators) – Vedanta Biosciences Vedanta Biosciences presented new pharmacokinetics data […]
Microbiome – October 2020 Microbiome – October 2020 US FDA granted IND approval for Seed Health’s DS-01 microbiota therapy in Irritable Bowel Syndrome 29 Sep 2020 DS-01 (broad spectrum probiotic) – Seed Health FDA granted new IND approval to Seed […]
Microbiome – October 2020 Microbiome – October 2020 Enterome’s Phase 2a trial first patient dosed with Sibofimloc for Crohn’s disease (CD) 23 Sep 2020 Sibofimloc (EB8018/TAK-018; FimH antagonist) – Enterome/ Takeda First patient has been dosed in a Phase 2a […]
